|Bid||33.57 x 51100|
|Ask||33.58 x 25600|
|Day's range||33.48 - 34.38|
|52-week range||27.37 - 40.79|
|Beta (5Y monthly)||0.47|
|PE ratio (TTM)||45.36|
|Forward dividend & yield||0.24 (0.71%)|
|Ex-dividend date||11 May 2022|
|1y target est||33.79|
ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.
Joining me on the call today are our chief executive officer, Mick Farrell, and chief financial officer, Brett Sandercock. Following our prepared remarks, we will host a Q&A session, and Mick and Brett will be joined by Rob Douglas, president and chief operating officer, and David Pendarvis, chief administrative officer and global general counsel.
ResMed (RMD) delivered earnings and revenue surprises of 0.68% and 0.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?